Last reviewed 2026-04-19 · How we verify

BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

1 treatments

Approved treatments

Anktiva · Altor Bioscience, Llc, An Indirect Wholly-Owned Su
Anktiva works by targeting a specific target to treat BCG-unresponsive nonmuscle invasive bladder cancer.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

Frequently asked questions about BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

What drugs treat BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors?

Tracked treatments include Anktiva.

What is the treatment for BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors?

Standard treatment for BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors includes Anktiva. See the treatment landscape page for first-line, second-line and salvage options.

Treatment landscape: BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors patent cliff · BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors CI report
Treatment: Anktiva · Altor Bioscience, Llc, An Indirect Wholly-Owned Su
All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing